Population Pharmacokinetics and Pharmacodynamics of Depemokimab in People with Asthma and Chronic Rhinosinusitis with Nasal Polyps. | ClinicLens
Depemokimab is the first ultra-long-acting biologic with enhanced interleukin-5 (IL-5) binding affinity, high potency, and extended half-life, enabling twice-yearly dosing. Depemokimab has demonstrated efficacy and safety in patients with asthma and chronic rhinosinusitis with na
Medical Literature · Updated
← Back to articlesIf the embedded page does not load in your browser, open it directly.